These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 2028945

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study.
    Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC.
    Hepatology; 1991 Apr; 13(4):627-31. PubMed ID: 2010157
    [Abstract] [Full Text] [Related]

  • 3. A 13-year longitudinal study of the impact of double mutations in the core promoter region of hepatitis B virus on HBeAg seroconversion and disease progression in patients with genotype C chronic active hepatitis.
    Jang JW, Lee YC, Kim MS, Lee SY, Bae SH, Choi JY, Yoon SK.
    J Viral Hepat; 2007 Mar; 14(3):169-75. PubMed ID: 17305882
    [Abstract] [Full Text] [Related]

  • 4. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients.
    Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, Lu SN, Changchien CS.
    Gastroenterology; 2007 Nov; 133(5):1466-74. PubMed ID: 17915220
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic hepatitis B virus infection.
    Bozkaya H, Ayola B, Lok AS.
    Hepatology; 1996 Jul; 24(1):32-7. PubMed ID: 8707278
    [Abstract] [Full Text] [Related]

  • 7. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
    Yalçin K, Değertekin H, Kokoğlu OF, Ayaz C.
    Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
    [Abstract] [Full Text] [Related]

  • 8. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
    Sponseller CA, Bacon BR, Di Bisceglie AM.
    Liver Transpl; 2000 Nov; 6(6):715-20. PubMed ID: 11084057
    [Abstract] [Full Text] [Related]

  • 9. Clinical presentation and natural history of chronic persistent hepatitis. A multicentre retrospective study on 1197 cases.
    Giusti G, Galanti B, Gaeta GB, Sagnelli E, Piccinino F, Ruggiero G.
    Ital J Gastroenterol; 1991 Nov; 23(3):111-8. PubMed ID: 1742503
    [Abstract] [Full Text] [Related]

  • 10. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma.
    Yuen MF, Sablon E, Yuan HJ, Wong DK, Hui CK, Wong BC, Chan AO, Lai CL.
    Hepatology; 2003 Mar; 37(3):562-7. PubMed ID: 12601354
    [Abstract] [Full Text] [Related]

  • 11. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels.
    Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF.
    Am J Med; 2004 Jun 15; 116(12):829-34. PubMed ID: 15178498
    [Abstract] [Full Text] [Related]

  • 12. The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression. A prospective cohort study.
    Zacharakis G, Koskinas J, Kotsiou S, Tzara F, Vafeiadis N, Papoutselis M, Maltezos E, Sivridis E, Papoutselis K.
    J Hepatol; 2008 Dec 15; 49(6):884-91. PubMed ID: 18674840
    [Abstract] [Full Text] [Related]

  • 13. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.
    Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, Liaw YF.
    Hepatology; 2002 Jun 15; 35(6):1522-7. PubMed ID: 12029639
    [Abstract] [Full Text] [Related]

  • 14. Evolution of HBeAg/anti-HBe status and its relationship to clinical and histological outcome in chronic HBV carriers in childhood.
    Sodeyama T, Kiyosawa K, Akahane Y, Tanaka E, Wada S, Oike Y, Nakamura M, Yoda H, Imai Y, Gibo Y.
    Am J Gastroenterol; 1986 Apr 15; 81(4):239-45. PubMed ID: 3962948
    [Abstract] [Full Text] [Related]

  • 15. The long-term course of chronic hepatitis B.
    Di Marco V, Lo Iacono O, Cammà C, Vaccaro A, Giunta M, Martorana G, Fuschi P, Almasio PL, Craxì A.
    Hepatology; 1999 Jul 15; 30(1):257-64. PubMed ID: 10385664
    [Abstract] [Full Text] [Related]

  • 16. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
    Castells L, Vargas V, Rodríguez F, Allende H, Buti M, Sánchez-Avila JF, Jardí R, Margarit C, Pumarola T, Esteban R, Guardia J.
    Liver Transpl; 2002 Oct 15; 8(10):892-900. PubMed ID: 12360430
    [Abstract] [Full Text] [Related]

  • 17. Changes in serological markers of hepatitis B virus after renal transplantation.
    Urbini Dos Santos C, Sevá-Pereira T, Alves-Filho G, Lorena SL, Soares EC, Mazzali M.
    Transplant Proc; 2008 Apr 15; 40(3):749-51. PubMed ID: 18455006
    [Abstract] [Full Text] [Related]

  • 18. The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis.
    Kilic ZM, Kuran S, Akdogan M, Cicek B, Oguz D, Odemis B, Sasmaz N.
    Adv Ther; 2008 Mar 15; 25(3):190-200. PubMed ID: 18385953
    [Abstract] [Full Text] [Related]

  • 19. [The prospective study of the clinical features and outcome of HBeAg-negative and HBeAg-positive cirrhosis in patients with chronic type B hepatitis].
    Ma H, Guo F, Wei L, Sun Y, Wang H.
    Zhonghua Yi Xue Za Zhi; 2007 Jul 10; 87(26):1832-5. PubMed ID: 17922993
    [Abstract] [Full Text] [Related]

  • 20. Natural history of hepatitis B.
    Marcellin P, Castelnau C, Martinot-Peignoux M, Boyer N.
    Minerva Gastroenterol Dietol; 2005 Mar 10; 51(1):63-75. PubMed ID: 15756147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.